Category: Joint ventures/collaborations
-
Pharma, Biotech Partner on Off-the-Shelf Cell Therapies
A biotechnology enterprise is teaming with a pharmaceutical company to develop off-the-shelf therapies for malfunctioning mitochondria, energy centers of cells.
-
Fine-Tuning Process Devised for Gene Therapies
Researchers designed a technique to adjust the volume of proteins from gene therapy released into patients, providing more control for complex diseases.
-
Trial Tests Psychedelic Drug Safety, Chemical Activity
A clinical trial is underway that tests an hallucinogenic compound among healthy adults as a potential treatment for mental health disorders.
-
Trial to Test Antibody Drug for Alzheimer’s Prevention
Eli Lilly and Company is partnering with an Alzheimer’s disease research center to test a synthetic antibody for preventing the disorder in at-risk individuals.
-
Univ. Lab Testing Wearable Respiratory Monitor
Medical researchers are assessing the feasibility of a wearable device to detect advance indicators of chronic respiratory disease symptoms.
-
GSK, Biotech Partner on Neuro Antibodies in $2.2B Deal
GlaxoSmithKline and biotechnology company Alector Inc. agreed to co-develop two synthetic antibodies for treating neurodegenerative disorders.
-
Trial Shows In-Body Crispr Therapy Feasibility
Early clinical trial data show gene editing with Crispr performed inside the body can correct an inherited neurological condition, with few adverse effects.
-
Biotechs Partner on Lower Cost AI-Designed Drugs
Two biotechnology companies are collaborating on discovery and development of new drugs designed with artificial intelligence, at lower cost to patients.
-
Biotechs Partner on Crispr Therapies for Neuro Disorders
Two biotechnology companies are designing therapies to deliver edited genes to treat Friedreich’s ataxia and amyotrophic lateral sclerosis, or ALS.
-
Diverse Genomic Variation Analytics Panel Created
A synthetic biology company and genetics research service are providing analytics on population genomic variations they say are more racially and ethnically diverse.